Cases and resources in vascular techniques

This PVI 2025 session brings clarity to one of the most urgent challenges in vascular medicine: acute PE —from setting up a PERT to current management strategies, catheter-guided thrombectomy, and treatment outcomes. It also highlights how PE can arise as a complication of venous interventions, offering essential insights for improving patient safety and response pathways.

This PVI 2025 session reviews practical strategies for managing complex AAA, from improving F/BEVAR outcomes and avoiding technical pitfalls to designing successful repairs and choosing between open and endovascular treatment for TAAA. A concise overview of the key principles guiding safer, smarter aortic interventions.

Dr. Per Skoog reviews the SWEDEPAD I and II trials, the largest PAD studies evaluating drug-eluting devices. SWEDEPAD I focused on CLTI patients, SWEDEPAD II on claudicants. Both studies showed no improvement in patient-centered outcomes compared with non-coated devices. These findings highlight that drug-eluting devices did not provide added benefit, offering key insights for everyday PAD management.

The PVI 2025 session covers access strategies, lesion preparation, near-occlusion and restenosis management, TCAR in challenging patients, and carotid dissections. Practical insights and advanced techniques are shared to tailor interventions to each patient.

This PVI 2025 session tackles some of the most persistent questions in endovascular therapy — from choosing CERAB or kissing stents for AIOD, to whether CFA guidelines are pushing boundaries or still holding back progress. It reviews the ongoing debate around stenting in distal popliteal disease, highlights what the SWEDEPAD RCT means for daily practice, and revisits the long-standing promise of resorbable scaffolds. A compact tour of key controversies shaping treatment choices today.

An 84-year-old man with prior TAVI presented with TIA symptoms. Imaging revealed left ICA occlusion and subocclusive right ICA stenosis, posing a high-risk management challenge.

Prof. Kak Khee Yeung and Dr. Juliette Raffort-Lareyre discuss how artificial intelligence could enhance image interpretation, guide pre-surgical planning and patient follow-up, and help develop predictive models. They also highlight the importance of international collaboration and patient data protection to advance AI in vascular medicine.

Missed the live webinar or want to revisit it? Watch the first PVI webinar replay, where experts discuss the SWEDEPAD 2 trial’s design, patient-reported outcomes for claudication, surrogate versus clinical endpoints, lesion types, class effects for DES/DCB, and implications for practice, recommendations, and future studies.

Get a preview of two major UK randomised controlled trials, RAVE and RAF, set to launch between early and mid-2026. Prof. Athanasios Saratzis outlines these crucial studies: RAVE focuses on comparing IVL with other techniques for challenging calcified arteries, while RAF addresses common femoral artery (CFA) disease by comparing open surgery to modern endovascular approaches. Discover how these trials are expected to redefine future PAD management.

Chronic limb-threatening ischemia (CLTI) carries high risks of amputation and mortality. Beyond clinical factors, socioeconomic disparities can strongly influence outcomes by affecting access to care, timing of interventions, and follow-up: an issue amplified during the COVID-19 pandemic. This study examines how regional socioeconomic status impacts post-revascularisation outcomes, highlighting key public health implications.